Mr. Philippe Dubuc reports

THERATECHNOLOGIES SHAREHOLDERS APPROVE PROPOSED PLAN OF ARRANGEMENT TO BE ACQUIRED BY FUTURE PAK

Theratechnologies Inc. shareholders have approved the previously announced plan of arrangement under Chapter XVI -- Division II of the Business Corporations Act (Quebec) involving purchaser CB Biotechnology, LLC, an affiliate of Future Pak, LLC.

At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44 per cent of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, and by 97.43 per cent of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, excluding the votes cast by the shareholders required to be excluded pursuant to Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions.

The proposed arrangement remains subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Quebec following the hearing expected to take place on Sept. 16, 2025.

About Theratechnologies Inc.

Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care.

About Future Pak

Founded in 1977 and headquartered in Wixom, Mich., Future Pak, along with its affiliates, is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. Future Pak operates across retail, specialty and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.

We seek Safe Harbor.